After the new addition of molecular biological markers in the 2016 edition of the World Health Organization (WHO) CNS tumor classification (6), genetic testing plays an important role in the staging and treatment of MB, including CTNNB for the WNT group (57), TP53 for the SHH group (58), MYC or MYCN for group 3 (59), and methylation for group 4 (60); these mutations are strongly associated with poor prognosis in MB patients. Here, MYC is linked to central nervous system neoplasm.